NU553 Unit 6 Exam Preparation

Student Name

Purdue University Globle 

NU553 Advanced Pharmacology and Pharmacotherapeutics

Prof. Name

Date

NU553 Unit 6 Exam Preparation: Key Topics, Medication Review, and Practice Questions

Success on the NU553 Unit 6 Exam requires a strong understanding of cardiovascular pharmacology, hematologic disorders, hypertension, hyperlipidemia, heart failure, arrhythmias, and evidence-based medication management. Students should focus on drug mechanisms of action, adverse effects, monitoring parameters, contraindications, reversal agents, and clinical decision-making. Mastering these concepts will improve both exam performance and real-world clinical reasoning.

The following study guide summarizes the highest-yield concepts while incorporating current clinical practice recommendations and pharmacology principles.

Thromboembolic Disorders

Thromboembolic disorders occur when blood clots develop within blood vessels and obstruct normal circulation. Pharmacologic management aims to prevent clot formation, reduce embolic events, and minimize bleeding complications.

Anticoagulant Medications

Students should understand the major anticoagulant classes, including:

• Unfractionated heparin (UFH)

• Low-molecular-weight heparins (LMWH)

• Warfarin

• Direct oral anticoagulants (DOACs)

For each medication, understand:

• Mechanism of action

• Indications

• Laboratory monitoring

• Contraindications

• Major adverse effects

• Drug interactions

• Available reversal agents

Antiplatelet Medications

Common antiplatelet medications include:

• Aspirin

• Clopidogrel

• Prasugrel

• Ticagrelor

Important review areas include platelet inhibition mechanisms, bleeding risks, perioperative management, and dual antiplatelet therapy recommendations after acute coronary syndrome or coronary stenting.

Key Clinical Concepts

Warfarin has a delayed onset of action because it inhibits vitamin K-dependent clotting factor synthesis. High-risk patients, particularly those with mechanical heart valves, often require temporary heparin therapy until the International Normalized Ratio (INR) reaches the therapeutic range.

Anemias

Anemia is categorized according to its underlying cause and red blood cell characteristics. Accurate diagnosis requires interpretation of laboratory findings alongside patient history and clinical presentation.

Iron Deficiency Anemia

Common laboratory findings include:

• Low ferritin

• Low serum iron

• Elevated total iron-binding capacity (TIBC)

• Microcytic, hypochromic red blood cells

Treatment generally consists of oral or intravenous iron supplementation.

Vitamin B12 Deficiency

Characteristic findings include:

• Macrocytic anemia

• Elevated methylmalonic acid

• Elevated homocysteine

• Neurologic manifestations

Patients with neurologic symptoms typically require intramuscular cyanocobalamin replacement before transitioning to maintenance therapy when appropriate.

Folate Deficiency

Typical findings include:

• Macrocytic anemia

• Elevated homocysteine

• Normal methylmalonic acid

Treatment consists of folic acid supplementation while ensuring vitamin B12 deficiency has been excluded.

Other Important Types

Students should also review:

• Anemia of chronic disease

• Chronic kidney disease-associated anemia

• Sickle cell disease

• Thalassemia

• Aplastic anemia

For each condition, understand:

• Pathophysiology

• Characteristic laboratory findings

• Pharmacologic treatment

• Common contraindications

• Monitoring recommendations

Hypertension

Hypertension management requires selecting medications based on patient comorbidities, cardiovascular risk, and current evidence-based guidelines.

Major Antihypertensive Drug Classes

Important medication classes include:

• ACE inhibitors

• Angiotensin receptor blockers (ARBs)

• Thiazide diuretics

• Loop diuretics

• Calcium channel blockers

• Beta blockers

• Mineralocorticoid receptor antagonists

For every class, students should know:

• Mechanism of action

• Common adverse effects

• Laboratory monitoring

• Contraindications

• Preferred clinical indications

High-Yield Clinical Pearls

• ACE inhibitors commonly produce a persistent dry cough because of increased bradykinin levels.

• Dihydropyridine calcium channel blockers frequently cause peripheral edema through arteriolar vasodilation.

• Monitoring renal function and potassium is essential when prescribing ACE inhibitors, ARBs, and potassium-sparing diuretics.

Hyperlipidemia

Hyperlipidemia treatment aims to reduce atherosclerotic cardiovascular disease (ASCVD) risk by lowering low-density lipoprotein cholesterol (LDL-C) and improving lipid profiles.

Understanding LDL and HDL

Low-density lipoprotein (LDL) transports cholesterol to peripheral tissues and contributes to plaque formation.

High-density lipoprotein (HDL) removes cholesterol from peripheral tissues and transports it back to the liver for elimination.

ASCVD Risk Assessment

ASCVD risk estimation helps determine:

• Statin eligibility

• Treatment intensity

• Long-term cardiovascular risk reduction

Coronary artery calcium (CAC) scoring may further guide statin therapy when treatment decisions remain uncertain.

Lipid-Lowering Medications

Students should understand:

• Statins

• Ezetimibe

• PCSK9 inhibitors

• Bile acid sequestrants

• Niacin

• Omega-3 fatty acids

• Fibrates

Review each medication’s:

• Mechanism

• Adverse effects

• Monitoring

• Contraindications

• Clinical indications

Patients with triglyceride levels of 300 mg/dL or higher should generally avoid bile acid sequestrants because these medications may further increase triglyceride concentrations.

Chronic Stable Angina and Myocardial Infarction

Management focuses on symptom relief, reducing myocardial oxygen demand, preventing thrombosis, and minimizing recurrent cardiovascular events.

Antianginal Medications

Review:

• Nitroglycerin

• Beta blockers

• Calcium channel blockers

• Ranolazine

Know each medication’s:

• Mechanism

• Side effects

• Drug interactions

• Contraindications

A daily nitrate-free interval of approximately 10 to 12 hours helps prevent nitrate tolerance.

Secondary Prevention After Myocardial Infarction

Standard secondary prevention often includes:

• High-intensity statins

• Dual antiplatelet therapy when indicated

• Beta blockers

• ACE inhibitors or ARBs

• Lifestyle modification

• Smoking cessation

Heart Failure

Heart failure management emphasizes symptom improvement, reduced hospitalization, and decreased mortality.

Guideline-Directed Medical Therapy

Core medication classes include:

• ACE inhibitors or ARBs

• Angiotensin receptor-neprilysin inhibitors (ARNIs)

• Evidence-based beta blockers

• Mineralocorticoid receptor antagonists

• Sodium-glucose cotransporter-2 (SGLT2) inhibitors

• Loop diuretics

Students should understand:

• Mechanism of action

• Mortality benefit

• Laboratory monitoring

• Contraindications

• Drug interactions

Verapamil should generally be avoided in heart failure with reduced ejection fraction (HFrEF) because of its negative inotropic effects.

Arrhythmias

Antiarrhythmic medications require careful patient selection because many agents can themselves produce serious arrhythmias.

Antiarrhythmic Drug Classes

Review:

• Class I sodium channel blockers

• Class II beta blockers

• Class III potassium channel blockers

• Class IV calcium channel blockers

For each class, understand:

• Mechanism

• ECG effects

• Monitoring

• Adverse reactions

• Contraindications

Flecainide should not be used in patients with structural heart disease, particularly coronary artery disease, because it increases the risk of life-threatening ventricular arrhythmias.

Practice Questions with Rationales

Question 1

Which patient requires heparin bridging when initiating warfarin therapy?

Correct Answer: B. A patient with a mechanical mitral valve beginning warfarin therapy.

Rationale: Mechanical heart valves carry a high risk of thromboembolism. Because warfarin requires several days to achieve therapeutic anticoagulation, heparin provides immediate protection during treatment initiation.

Question 2

A patient has macrocytic anemia, neuropathy, elevated methylmalonic acid, and elevated homocysteine. Which treatment is most appropriate?

Correct Answer: C. Intramuscular cyanocobalamin 1,000 mcg daily for one week.

Rationale: Neurologic manifestations strongly suggest vitamin B12 deficiency, which initially requires parenteral replacement.

Question 3

Which antihypertensive medication class most commonly causes a persistent dry cough?

Correct Answer: B. ACE inhibitors.

Rationale: Elevated bradykinin concentrations produce the characteristic chronic, nonproductive cough.

Question 4

Which medication class most commonly causes peripheral edema?

Correct Answer: C. Dihydropyridine calcium channel blockers.

Rationale: Arteriolar vasodilation increases capillary hydrostatic pressure, resulting in lower-extremity edema.

Question 5

Which lipid-lowering medication should generally be avoided in patients with triglycerides above 300 mg/dL?

Correct Answer: C. Bile acid sequestrants.

Rationale: These agents may significantly increase triglyceride levels.

Question 6

What is the most effective strategy for preventing nitrate tolerance?

Correct Answer: C. Maintain a daily nitrate-free interval of 10 to 12 hours.

Rationale: Continuous nitrate exposure results in tachyphylaxis and reduced therapeutic effectiveness.

Question 7

Which medication should be avoided in HFrEF because of negative inotropic effects?

Correct Answer: C. Verapamil.

Rationale: Verapamil can worsen systolic heart failure by reducing myocardial contractility.

Question 8

Which condition must be excluded before initiating flecainide?

Correct Answer: C. Coronary artery disease.

Rationale: Flecainide significantly increases the risk of proarrhythmic events in patients with structural heart disease.

Key Exam Takeaways

• Warfarin requires heparin bridging in patients at high thromboembolic risk.

• Elevated methylmalonic acid strongly indicates vitamin B12 deficiency.

• ACE inhibitors commonly cause a dry, persistent cough.

• Dihydropyridine calcium channel blockers frequently produce peripheral edema.

• Bile acid sequestrants should generally be avoided in severe hypertriglyceridemia.

• Daily nitrate-free intervals prevent nitrate tolerance.

• Verapamil is contraindicated in HFrEF.

• Flecainide should not be prescribed to patients with coronary artery disease or significant structural heart disease.

Frequently Asked Questions (FAQs)

What topics are most important for the NU553 Unit 6 exam?

The highest-yield topics include anticoagulants, antiplatelet drugs, anemia management, hypertension medications, lipid-lowering therapy, heart failure treatment, myocardial infarction management, and antiarrhythmic pharmacology.

Why is heparin used when starting warfarin?

Heparin provides immediate anticoagulation because warfarin requires several days to inhibit vitamin K-dependent clotting factors and achieve a therapeutic INR.

How can vitamin B12 deficiency be distinguished from folate deficiency?

Both conditions cause macrocytic anemia, but vitamin B12 deficiency also elevates methylmalonic acid and often causes neurologic symptoms such as peripheral neuropathy.

Which antihypertensive medications require routine laboratory monitoring?

ACE inhibitors, ARBs, mineralocorticoid receptor antagonists, and many diuretics require monitoring of renal function and serum electrolyte levels.

Why is verapamil avoided in heart failure with reduced ejection fraction?

Verapamil decreases myocardial contractility and may worsen symptoms or increase the risk of heart failure decompensation.

Patients with mechanical heart valves require temporary heparin bridging when warfarin therapy is initiated because warfarin has a delayed onset of action. Vitamin B12 deficiency is identified by elevated methylmalonic acid, macrocytic anemia, and neurologic symptoms. ACE inhibitors commonly cause a persistent dry cough, while dihydropyridine calcium channel blockers frequently cause peripheral edema. Verapamil is contraindicated in heart failure with reduced ejection fraction because of its negative inotropic effects, and flecainide should not be used in patients with coronary artery disease due to an increased risk of proarrhythmia.

References

American College of Cardiology. (2023). ACC/AHA guideline resources for cardiovascular disease management. https://www.acc.org

American Diabetes Association. (2025). Standards of care in diabetes—2025. Diabetes Care, 48(Supplement_1). https://diabetesjournals.org/care

Brunton, L. L., Hilal-Dandan, R., & Knollmann, B. C. (Eds.). (2023). Goodman & Gilman’s the pharmacological basis of therapeutics (14th ed.). McGraw Hill. https://accessmedicine.mhmedical.com

NU553 Unit 6 Exam Preparation

Katzung, B. G. (2024). Basic and clinical pharmacology (16th ed.). McGraw Hill. https://accessmedicine.mhmedical.com

McCance, K. L., & Huether, S. E. (2023). Pathophysiology: The biologic basis for disease in adults and children (9th ed.). Elsevier. https://www.elsevier.com

Whelton, P. K., Carey, R. M., Aronow, W. S., et al. (2024). Guideline for the prevention, detection, evaluation, and management of high blood pressure in adults. Hypertension. https://www.ahajournals.org/journal/hyp

Yancy, C. W., Maddox, T. M., Januzzi, J. L., et al. (2024). 2024 ACC expert consensus decision pathway for heart failure management. Journal of the American College of Cardiology. https://www.jacc.org